Skip to main content

Table 2 Incidence (per 100 person-years) of new-onset AF in diabetic patients taking metformin plus DPP4i or other hypoglycemic agents

From: Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

  New-onset AF
Numbers Events Incidence before weighting Incidence after weighting HRa
95% CI
P value
DPP4i 16,017 45 0.14 (0.10–0.18) 0.14 (0.12–0.15)* 1.00
(Reference)
Other hypoglycemic agents rather than DPP4i 74,863 386 0.21 (0.19–0.24) 0.21 (0.19–0.23) 1.53
(1.31–1.78)
P < 0.0001
Sulfonylurea 62,216 318 0.20 (0.18–0.23) 0.20 (0.18–0.23) 1.45
(1.24–1.70)
P < 0.0001
Alpha glucosidase inhibitor 5091 24 0.24 (0.14–0.33) 0.23 (0.15–0.32) 1.75
(1.19–2.57)
P = 0.0045
Meglitinide 5164 41 0.38 (0.26–0.49) 0.38 (0.27–0.48) 2.78
(2.05–3.76)
P < 0.0001
TZD 3091 15 0.23 (0.11–0.34) 0.23 (0.12–0.33) 1.68
(1.05–2.69)
P = 0.0307
Insulin 1361 3 0.11 (0.02–0.32) 0.11 (0.03–0.29) 0.79
(0.28–2.26)
P = 0.20
GLP1 5 0    
  1. There were 2016 patients taking more than two hypoglycemic agents as second-line hypoglycemic agents at the same time
  2. ACEI angiotensin-converting-enzyme inhibitor, AF atrial fibrillation, ARB angiotensin II receptor antagonists, CI confidence interval, DM diabetes mellitus, DPP4i dipeptidyl peptidase-4 inhibitor, GLP-1 glucagon-like peptide-1; PAOD peripheral arterial obstructive disease, TZD thiazolidinedione
  3. aFor other hypoglycemic agents versus DPP-4 inhibitors (reference) after propensity score weighting